NASDAQ: PCVXVaxcyte Inc Stock
$60.88-0.72 (-1.17%)
Updated Apr 23, 2024
PCVX Price
$60.88
Fair Value Price
$3.79
Market Cap
$6.60B
52 Week Low
$41.57
52 Week High
$82.04
P/E
-14.71x
P/B
5.32x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$402.27M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
-$297M
Beta
0.88
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PCVX Overview
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PCVX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PCVX ($60.88) is overvalued by 1,506.34% relative to our estimate of its Fair Value price of $3.79 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PCVX ($60.88) is not significantly undervalued (1,506.34%) relative to our estimate of its Fair Value price of $3.79 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PCVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PCVX due diligence checks available for Premium users.
Be the first to know about important PCVX news, forecast changes, insider trades & much more!
PCVX News
Valuation
PCVX fair value
Fair Value of PCVX stock based on Discounted Cash Flow (DCF)
Price
$60.88
Fair Value
$3.79
Overvalued by
1,506.34%
PCVX ($60.88) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PCVX ($60.88) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PCVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PCVX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-14.71x
Industry
16.46x
Market
41.92x
PCVX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.32x
Industry
5.93x
PCVX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PCVX's financial health
Profit margin
Revenue
$0.0
Net Income
-$180.8M
Profit Margin
0%
PCVX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$1.4B
Liabilities
$167.4M
Debt to equity
0.14
PCVX's short-term assets ($1.10B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PCVX's short-term assets ($1.10B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PCVX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PCVX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$128.8M
Investing
-$13.9M
Financing
$2.7M
PCVX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PCVX vs Biotech Stocks
Vaxcyte Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.